Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer

Advances in Experimental Medicine and Biology

Volumn 539 A, Issue , 2004, Pages 111-119

  Lahme, Sven ^a   Bichler, Karl Horst ^a   Feil, Gerhard ^a   Zumbrägel, Andreas ^a   Götz, Tobias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN; PROTEIN P22; NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; URINE CYTOLOGY; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CYTOLOGY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; URINE; UROLITHIASIS;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINARY CALCULI; URINE;

EID: 2342507193     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (14)

1. Abbate I, D'Introno A, Cardo G, Marano A, Addabbo L, Musci MD, et al: Comparision of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res, 18(5b):3803, 1998.
2. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, et al: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol, 156 (4):1280, 1996.
3. Chen YT, Hayden CL, Marchand KJ, Makuch RW: Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol, 158(5):1899, 1997.
4. Del-Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, et al: Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol, 35 (2):93, 1999.
5. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al: Comparision for screening methods in the detection of bladder cancer. J Urol, 161(2):388, 1999.
6. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC: Sensitivity and specificity of NMP-22, telomerase and BTA in the detection of human bladder cancer. Urology, 52(3):398, 1998.
7. Lüdecke G, Edler M, Miller J, Fischer C, Kraus S, Weidner W: Nuclear matrix protein (NMP 22) - a powerful urine marker in tumor screening and follow-up in bladder cancer. Anticancer Res, 17:4204, 1997.
8. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ootani M, et al: Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol, 6(4):173, 1999.
9. Miyanaga N, Akaza H, Ishikawa S, Ootani M, Noguchi R, Kawai K, et al: Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol, 31 (2):163, 1997.
10. Serretta V, Lo-Presti D, Vasile P, Gange E, Espositi E, Menozzi I: Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology, 52(5):793, 1998.
11. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specifity and positive predictive value of NMP22 and BTA stat. J Urol, 162 (1):53, 1999.
12. Shelfo SW, Solowax MS: The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol, 15(2):107, 1997.
13. Soloway MS, Briggman V, Carpinitio GA, Chodak GW, Church PA, Lamm DI, et al: Use of a new tumor marker, urinary NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol, 156:363, 1996.
14. Sozen S, Biri H, Sinik Z, Kupeli B, Alkibay T, Bozkirli I: Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol, 36(3):225, 1999.